Setti
Bharatram Setti, Bangalore IN
Patent application number | Description | Published |
---|---|---|
20130155875 | PUSH-TO-TALK-OVER-CELLULAR (POC) - A Push-to-Talk-over Cellular (PoC) implementation for use in a wireless communications network, wherein one or more servers interface to the wireless communications network to perform the PoC call sessions. Both the servers and the mobile units that use the PoC call sessions communicate with each other using SIP/IP (Session Initiation Protocol/Internet Protocol) control messages within the wireless communications network, and one or more of the servers switches RTP/IP (Realtime Transport Protocol/Internet Protocol), RTCP/IP (Realtime Transport Control Protocol/Internet Protocol), or MBCP/IP (Media Burst Control Protocol/Internet Protocol) voice packets for the PoC call sessions between the mobile units across the wireless communications network. | 06-20-2013 |
Dario Setti, Muenchen DE
Patent application number | Description | Published |
---|---|---|
20110085230 | METHOD FOR CONTROLLING AN ERBIUM DOPED FIBER AMPLIFIER (EDFA) AND AMPLIFIER ARRANGEMENT - The invention refers to a method for operating an amplifier with a first amplifier stage (A | 04-14-2011 |
Dario Setti, Munchen DE
Patent application number | Description | Published |
---|---|---|
20090303577 | Optical Amplifier Configuration - An optical amplifier configuration for WDM (wavelength division multiplex) systems uses a common pump source connected to an input of an optical splitter deploying pump light via variable optical attenuators to a plurality of optical amplifiers. Control circuits determine individually the output powers of the amplifiers by varying the attenuations of the variable optical attenuators. Amplifier units based on PLC technology are implemented to reduce the size. | 12-10-2009 |
20120275782 | METHOD AND APPARATUS FOR PREVENTING SIGNAL INTERFERENCE IN A PASSIVE OPTICAL NETWORK - A method removes signal interference in a passive optical network. The passive optical network includes an optical line terminal, a splitting unit coupled with the optical line terminal, an optical network unit coupled with the splitting unit, and an identification signal uniquely associated with the optical network unit. The method includes the steps of sending a first signal, detecting the first signal, comparing the detected first signal with an identification signal and decoupling the optical network unit from the splitting unit if the comparing step results in a mismatch. | 11-01-2012 |
Eduardo Setti, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20130245014 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 09-19-2013 |
20150150874 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 06-04-2015 |
Eduardo Setti, San Mateo, CA US
Patent application number | Description | Published |
---|---|---|
20100317659 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 12-16-2010 |
20110118245 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O) | 05-19-2011 |
20110269740 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are pyrrolotriazine compounds for treatment of JAK kinase, including JAK2 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 11-03-2011 |
20130296363 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS - Provided herein are compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 11-07-2013 |
20140045868 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. | 02-13-2014 |
20140194449 | OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein is an optically active pyrozolylaminoquinazaline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a proliferative disease, inflammatory disease, or renal disease. | 07-10-2014 |
20150141443 | OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein is an optically active pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a proliferative disease, inflammatory disease, or renal disease. | 05-21-2015 |
20150246042 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. | 09-03-2015 |
20150353528 | OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein is an optically active pyrozolylaminoquinazaline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a proliferative disease, inflammatory disease, or renal disease. | 12-10-2015 |
Eduardo Setti, Fremont, CA US
Patent application number | Description | Published |
---|---|---|
20130317045 | THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are thienopyridine and thienopyrimidine compounds of formula (I) for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 11-28-2013 |
Eduardo L. Setti, San Mateo, CA US
Patent application number | Description | Published |
---|---|---|
20090023781 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors - The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. | 01-22-2009 |
Lina Setti, Fremont, CA US
Patent application number | Description | Published |
---|---|---|
20140275003 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) | 09-18-2014 |
Lina Setti, South San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20150315198 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS - In one aspect this invention relates generally to compounds of Formula: | 11-05-2015 |
Lina Setti, Emeryville, CA US
Patent application number | Description | Published |
---|---|---|
20160038504 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent. | 02-11-2016 |
Lina Quattrocchio Setti, Fremont, CA US
Patent application number | Description | Published |
---|---|---|
20160038504 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent. | 02-11-2016 |
Sridhar Setti, Beaverton, OR US
Patent application number | Description | Published |
---|---|---|
20130197679 | Multi-Activity Platform and Interface - A multi-activity system may be configured to receive, upload, synchronize and process data for a variety of different activity types and/or recorded using multiple types of activity monitoring devices. In one example, an application interface may be defined with a multiple functions that are each useable by various types of devices and for processing multiple types of data. Additionally or alternatively, data for different activity types and/or recorded using different types of monitoring devices may be processed differently. Synchronization of data may further be handled on a device-by-device basis, device-type basis and/or activity-type basis using various tracking parameters. | 08-01-2013 |
Stefania Setti, Carpi IT
Patent application number | Description | Published |
---|---|---|
20090299128 | DEVICE FOR THE REGENERATION AND PREVENTION OF DEGENERATION OF THE CARTILAGINOUS TISSUE AND SUBCHRONDRAL BONE AND THE PROLIFERATION OF CHONDROCYTES BY MEANS OF A PULSED ELECTROMAGNETIC FIELD - Device for the regeneration and prevention of degeneration of the cartilage and subchondral bone and the proliferation of chondrocytes by means of electromagnetic waves comprising a device for generating a periodic signal u(t) and a power amplifier suitable for applying the signal u(t) to a pair of solenoids for the generation of an electromagnetic field M(t) addressed towards a portion of human/animal body containing cartilage. Setting means are provided for the generation of an electromagnetic field having intensity between 0.2 and 2 milliTesla, frequency between 37 and 75 Hz and period of application between 1 hour and 9 hours. | 12-03-2009 |